These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33148660)

  • 21. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer.
    Gibson JT; Orlandella RM; Turbitt WJ; Behring M; Manne U; Sorge RE; Norian LA
    Front Immunol; 2020; 11():590794. PubMed ID: 33123173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast.
    Guo X; Fan Y; Lang R; Gu F; Chen L; Cui L; Pringle GA; Zhang X; Fu L
    Mod Pathol; 2008 Sep; 21(9):1101-7. PubMed ID: 18469794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma.
    Choi S; Lee KW; Koh HH; Park S; Yeo SY; Joh JW; Choi MS; Kim SH; Park CK; Ha SY
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3517-3534. PubMed ID: 34462784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation.
    Ryu MS; Woo MY; Kwon D; Hong AE; Song KY; Park S; Lim IK
    Exp Cell Res; 2014 Oct; 327(2):209-21. PubMed ID: 25088256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
    Zhu S; Lin J; Qiao G; Xu Y; Zou H
    Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COPS6 promotes tumor progression and reduces CD8
    Du WQ; Zhu ZM; Jiang X; Kang MJ; Pei DS
    Acta Pharmacol Sin; 2023 Sep; 44(9):1890-1905. PubMed ID: 37095198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
    Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
    Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant
    Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
    Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
    Chen Y; Zhang B; Bao L; Jin L; Yang M; Peng Y; Kumar A; Wang JE; Wang C; Zou X; Xing C; Wang Y; Luo W
    J Clin Invest; 2018 May; 128(5):1937-1955. PubMed ID: 29629903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model.
    Yuan CH; Yang XQ; Zhu CL; Liu SP; Wang BC; Wang FB
    Asian Pac J Cancer Prev; 2014; 15(1):265-71. PubMed ID: 24528037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.
    Morello G; Cancila V; La Rosa M; Germano G; Lecis D; Amodio V; Zanardi F; Iannelli F; Greco D; La Paglia L; Fiannaca A; Urso AM; Graziano G; Ferrari F; Pupa SM; Sangaletti S; Chiodoni C; Pruneri G; Bardelli A; Colombo MP; Tripodo C
    Cancer Immunol Res; 2021 Jul; 9(7):825-837. PubMed ID: 33941587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.